Effect of Alirocumab(proprotein convertase subtilisin/kexin type9 inhibitor) and Rosuvastatin or Rosuvastatin alone on lipid core plaques in coronary artery disease evaluated by near-infrared spectroscopy intravascular ultrasound
- Conditions
- angina pectoris
- Registration Number
- JPRN-UMIN000031243
- Lead Sponsor
- Kobe University,department of cardiology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
Patients who have received one or more doses of anti-PCSK9 monoclonal antibody. Patients who experienced poorly controlled high blood pressure (systolic blood pressure>180 mmHg or diastolic blood pressure>110 mmHg measured more than once) between the time of PCI and randomization. Patients with LDL-Chol value <70 mg/dl. Patients with allergic drug hypersensitivity to drugs to be used. Patients with a history of hemorrhagic stroke. Patients receiving treatment for anticancer drugs. Patients undergoing LDL apheresis. Patients with serious liver and kidney dysfunction. Patients who conflict with any of the warning contraindications listed in the Rosuvastatin national package insert. Patients contradicting the contraindications listed in the Pralient's national package insert. Pregnant women and pregnant or lactating patients. Others Patients judged inappropriate by the doctor in charge of this exam.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We investigate the change in the maxLCBI (4 mm) value calculated by NIRS-IVUS test at the time of PCI and treatment evaluation (week 36) in the group of Alirocumab and standard treatment (statin alone).
- Secondary Outcome Measures
Name Time Method CBI(lesion), Angle of lipid core, EEM CSA, Lumen CSA, Minimum lumen diameter, Plaque burden, Lesion length